Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2000. Start Trial.
Date Value
September 30, 2026 1.810M
June 30, 2026 1.810M
March 31, 2026 1.810M
December 31, 2025 1.935M
September 30, 2025 1.935M
June 30, 2025 1.848M
March 31, 2025 0.5375M
December 31, 2024 0.5172M
September 30, 2024 4.805M
June 30, 2024 4.467M
March 31, 2024 4.435M
December 31, 2023 4.435M
September 30, 2023 4.331M
June 30, 2023 4.331M
March 31, 2023 4.331M
December 31, 2022 4.321M
September 30, 2022 4.321M
June 30, 2022 4.321M
March 31, 2022 4.313M
December 31, 2021 4.302M
September 30, 2021 4.239M
June 30, 2021 4.066M
March 31, 2021 2.653M
December 31, 2020 2.590M
September 30, 2020 2.590M
Date Value
June 30, 2020 2.565M
March 31, 2020 2.565M
December 31, 2019 2.565M
September 30, 2019 2.565M
June 30, 2019 2.565M
March 31, 2019 2.565M
December 31, 2018 2.565M
September 30, 2018 2.565M
June 30, 2018 2.565M
March 31, 2018 2.565M
December 31, 2017 2.565M
September 30, 2017 2.565M
June 30, 2017 2.565M
March 31, 2017 2.564M
December 31, 2016 2.564M
September 30, 2016 2.077M
June 30, 2016 0.0232M
March 31, 2016 0.0065M
June 30, 2015 0.0065M
March 31, 2015 0.0065M
December 31, 2014 0.0065M
September 30, 2011 0.0001M
June 30, 2011 0.0001M
March 31, 2011 0.0001M
December 31, 2010 0.0001M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Oncolytics Biotech, Inc. 132.21M
Sangamo Therapeutics, Inc. 414.27M
Sarepta Therapeutics, Inc. 107.23M
Anixa Biosciences, Inc. 34.58M
Vicapsys Life Sciences, Inc. 32.37M